BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/24/2022 8:11:15 AM | Browse: 630 | Download: 1968
Publication Name World Journal of Clinical Cases
Manuscript ID 67011
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Sintilimab-induced autoimmune diabetes: A case report and review of the literature
Manuscript Source Unsolicited Manuscript
All Author List Jing Yang, Ying Wang and Xiang-Min Tong
ORCID
Author(s) ORCID Number
Jing Yang http://orcid.org/0000-0002-7439-4802
Ying Wang http://orcid.org/0000-0003-2121-7025
Xiang-Min Tong http://orcid.org/0000-0002-4175-0321
Funding Agency and Grant Number
Funding Agency Grant Number
Key Research and Development Project of Science and Technology Department of Zhejiang Province 2019C03038
Corresponding Author Xiang-Min Tong, MD, PhD, Chief Physician, Department of Hematology, Clinical Trial Institute, Zhejiang Provincial People's Hospital, No. 158 Shangtang Road, Hangzhou 310014, Zhejiang Province, China. tongxiangmin@163.com
Key Words Sintilimab; Immune related adverse effects; Small cell lung cancer; Autoimmune diabetes; Case report
Core Tip We report a case of programmed cell death-1 (PD-1) inhibitor-induced autoimmune diabetes mellitus (DM) after treatment of small cell lung cancer, and reviewed some published cases (n = 36) of PD-1/PD-ligand 1 inhibitor-induced DM. Plasma glucose monitoring is significant for preventing the occurrence of diabetic ketoacidosis.
Publish Date 2022-01-24 08:11
Citation Yang J, Wang Y, Tong XM. Sintilimab-induced autoimmune diabetes: A case report and review of the literature. World J Clin Cases 2022; 10(4): 1263-1277
URL https://www.wjgnet.com/2307-8960/full/v10/i4/1263.htm
DOI https://dx.doi.org/10.12998/wjcc.v10.i4.1263
Full Article (PDF) WJCC-10-1263.pdf
Full Article (Word) WJCC-10-1263.docx